Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
Hubbell
HUBB
$26.8B
| $23.7M | 0.04% |
202,800
-121,800
| -38% | -$13.4M |
|
677
B2Gold
BTG
$6.7B
| $23.7M | 0.04% |
9,981,997
+1,346,500
| +16% | +$3.34M |
|
678
Trinity Industries
TRN
$2.34B
| $23.6M | 0.04% |
1,182,595
+413,089
| +54% | +$7.61M |
|
|
AUO
679
DELISTED
AU Optronics Corp
AUO
| $23.6M | 0.04% |
6,675,500
+715,916
| +12% | +$2.64M |
|
680
NMI Holdings
NMIH
$3.42B
| $23.6M | 0.04% |
2,217,700
+551,800
| +33% | +$4.88M |
|
|
UBNK
681
DELISTED
United Financial Bancorp, Inc.
UBNK
| $23.6M | 0.04% |
1,297,239
+93,700
| +8% | +$1.5M |
|
682
OGE Energy
OGE
$9.71B
| $23.5M | 0.04% |
703,200
+188,100
| +37% | +$5.94M |
|
|
ORC
683
Orchid Island Capital
ORC
$1.32B
| $23.5M | 0.04% |
433,560
+350,320
| +421% | +$18.7M |
|
|
CSBK
684
DELISTED
Clifton Bancorp Inc.
CSBK
| $23.5M | 0.04% |
1,386,162
+100,500
| +8% | +$1.61M |
|
685
Extreme Networks
EXTR
$3.16B
| $23.4M | 0.04% |
4,649,961
| – | – |
|
686
Essent Group
ESNT
$6.23B
| $23.3M | 0.04% |
721,200
-120,000
| -14% | -$3.53M |
|
687
Ferrari
RACE
$72.5B
| $23.3M | 0.04% |
400,299
+341,354
| +579% | +$18.6M |
|
688
Nokia
NOK
$59B
| $23.3M | 0.04% |
4,848,495
-12,363,480
| -72% | -$58.3M |
|
689
Culp Inc
CULP
$43.2M
| $23.3M | 0.04% |
627,300
-13,429
| -2% | -$434K |
|
690
FMC
FMC
$1.27B
| $23.2M | 0.04% |
+473,422
| New | +$21.6M |
|
691
Forrester Research
FORR
$224M
| $23.2M | 0.04% |
540,200
+6,582
| +1% | +$262K |
|
|
DFT
692
DELISTED
DuPont Fabros Technology Inc.
DFT
| $23.2M | 0.04% |
527,700
-241,900
| -31% | -$9.96M |
|
693
Qualys
QLYS
$6.78B
| $23.2M | 0.04% |
731,900
+116,100
| +19% | +$4.09M |
|
694
Deutsche Bank
DB
$72.1B
| $23.1M | 0.04% |
1,427,035
+490,672
| +52% | +$6.91M |
|
695
Photronics
PLAB
$1.97B
| $23M | 0.04% |
2,038,600
+51,005
| +3% | +$535K |
|
696
Axalta
AXTA
$7.93B
| $23M | 0.04% |
843,800
-61,100
| -7% | -$1.61M |
|
|
FDC
697
DELISTED
First Data Corporation
FDC
| $22.9M | 0.04% |
1,617,202
+1,363,002
| +536% | +$19.4M |
|
|
SPPI
698
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $22.9M | 0.04% |
5,177,312
-364,645
| -7% | -$1.53M |
|
|
TTSH
699
DELISTED
Tile Shop Holdings
TTSH
| $22.9M | 0.04% |
1,170,400
+151,400
| +15% | +$2.82M |
|
700
Donaldson
DCI
$11.1B
| $22.8M | 0.04% |
542,000
+352,100
| +185% | +$14M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.